Hikma Pharmaceuticals PLC (HIK) to Issue Dividend of $0.48 on May 1st

Hikma Pharmaceuticals PLC (LON:HIKGet Free Report) declared a dividend on Wednesday, February 26th, DividendData.Co.Uk reports. Shareholders of record on Thursday, March 20th will be paid a dividend of $0.48 per share on Thursday, May 1st. This represents a yield of 1.8%. The ex-dividend date is Thursday, March 20th. This is a 50.0% increase from Hikma Pharmaceuticals’s previous dividend of $0.32. The official announcement can be seen at this link.

Hikma Pharmaceuticals Price Performance

LON:HIK traded up GBX 22 ($0.29) during trading hours on Tuesday, hitting GBX 2,052 ($26.65). 76,300,625 shares of the stock traded hands, compared to its average volume of 3,417,024. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82. Hikma Pharmaceuticals has a 1 year low of GBX 1,750 ($22.73) and a 1 year high of GBX 2,360 ($30.65). The company has a market cap of £5.69 billion, a price-to-earnings ratio of 20.14, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. The stock has a 50 day moving average price of GBX 2,177.22 and a 200 day moving average price of GBX 2,014.40.

Analyst Ratings Changes

HIK has been the topic of several analyst reports. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Hikma Pharmaceuticals in a report on Friday, March 7th. Berenberg Bank reaffirmed a “buy” rating and set a GBX 2,560 ($33.25) price target on shares of Hikma Pharmaceuticals in a report on Monday, March 10th.

View Our Latest Report on HIK

About Hikma Pharmaceuticals

(Get Free Report)

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.

Featured Stories

Dividend History for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.